5240752022-07-012022-09-305240752022-09-305240752022-03-315240752022-04-012022-09-305240752022-07-012022-09-30in-bse-fin:OtherExpenses1Member5240752022-04-012022-09-30in-bse-fin:OtherExpenses1Member5240752022-07-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15240752022-04-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524075ALBERTDAVDINE155C01010ALBERT DAVID LIMITEDEquity2022-04-012023-03-312022-11-122022-11-03INRLakhsHalf yearlySingle segmentThe company is engaged in the manufacturing of pharmaceuticals and has only one reportable segment in accordance with Ind AS-108 "Operating Segment"2022-11-1211:30:002022-11-1212:45:00trueCash Flow IndirectNot applicable2022-07-012022-09-30UnauditedStandalone9237750001353100001059085000172071000162660000627900020906400012500002067900023123600080323900025584600002558460004730500071590005446400002013820000000201382000127900020266100000570720001035.2935.290035.2935.29 1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 12th November, 2022. The Limited Review for the quarter and half year ended 30th September, 2022 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LO&DR) Regulations, 2015. <BR> <BR> 2. The Statutory Auditors of the Company have issued an unmodified review report on the Unaudited Financial Results for the quarter ended 30th September,2022. <BR> <BR> 3. The Company is engaged in the manufacturing of pharmaceuticals and has only one reportable segment in accordance with Ind AS-108 "Operating Segments". <BR> <BR> 4. During the quarter the Company has made payment of dividend of Rs.9.00 per equity share of Rs.10/- each, total outflow amounting to Rs.513.64 Lakhs in respect of financial year ended on 31st March, 2022. <BR> <BR> 5. Figures for the previous periods are regrouped to conform to the figures of the current period as and when required in limited context of format of financial results and disclosures thereon specified by SEBI. <BR> 2022-04-012022-09-30UnauditedStandalone1855750000792860001935036000342374000313734000270530004353660002368000419080004725800001635383000299653000029965300087011000-6295000807160000218937000000021893700036800021930500000570720001038.3638.360038.3638.36Other Expenses231236000Other Expenses47258000080468800011041000031652000267825000032518800059301300023180001784500014605570003729510001717215000326093000380870008843300051574000257260002247128000209900004264300026837120004144269000570720002905579000296265100029626510000315200003152000011307800014459800003207590004294400007501990003436400020969500042762000103702000011816180004144269000236800018841000-7513200008035000132770002590001016000-35000010570000011050000419080000-16998000-8354000-22344000-571000-4660002956000161730000-3842000000-40750000-538820002457710000005973800001860330000000000034300060160000144583000000000000598000000000029560001095300000-7654700000000000000505000051014000140400000-574680005201800096400052982000-1489500038087000Items that will not be reclassified to profit or less974000974000Items that will not be reclassified to profit or less-243000-243000-305000-61100000